Catalog No.
Product Name
Application
Product Information
Citations
-
Herbicide
Butroxydim is an acetyl-coenzyme A carboxylase (ACCase) inhibitor utilized as a selective herbicide. This compound effectively targets and controls herbicide-resistant populations of Hordeum leporinum, demonstrating significant efficacy against strains resistant to other ACCase inhibitors. It is therefore valuable for researchers studying herbicide resistance mechanisms and developing effective weed management strategies. -
Herbicide
Carfentrazone-ethyl is a selective post-emergence herbicide that acts as a protoporphyrinogen oxidase (Protox) inhibitor, exhibiting an IC50 value of 18 nM against soybean Protox. This compound effectively disrupts the biosynthesis of chlorophyll and heme, leading to the rapid death of susceptible weeds, such as ivy-leaved morning glory and velvetleaf. Its primary applications include the control of broadleaf weeds in various agricultural settings, making it a valuable tool in herbicide research and development. -
Herbicide
Atraton is a 1,3,5-triazine herbicide that exerts its activity through selective inhibition of photosynthetic processes in target plants. This compound is noted for its photodegradability, undergoing degradation when activated by the photosensitizer acetone. Atraton is primarily utilized in agricultural research to study the effects of herbicide application and its environmental fate. -
Herbicide
Buminafos is an organophosphate herbicide that targets key enzymes involved in weed growth regulation. It exhibits broad-spectrum activity against various weed species, making it valuable for enhancing agricultural productivity. This reagent is primarily used for research applications related to herbicide efficacy and the mechanisms of herbicide resistance in crops. -
Herbicide
Flupropanate is a selective herbicide that functions as a plant growth inhibitor by disrupting radicle growth and lipid biosynthesis in susceptible plants. It effectively controls Stipa weeds, including Nassella neesiana and N. trichotoma, while reducing the prevalence of the invasive species Eragrostis curvula. Flupropanate shows sensitivity to gramineous plants like ryegrass but exhibits good tolerance in species such as plantain, chicory, and some legumes. Research indicates that in Mediterranean climates, Flupropanate has minimal non-target impact on native plant communities and endangered species, demonstrating its ecological safety. -
Herbicide
Sulfosate is a post-emergence, non-selective herbicide that functions by inhibiting the synthesis of essential amino acids in plants. It effectively controls a broad spectrum of weeds through translocation, making it useful in various agricultural applications. Sulfosate is particularly valuable in the management of challenging weed populations, facilitating improved crop yield and quality. -
Herbicide
Defenuron is a selective herbicide that inhibits the growth of undesirable grasses and broad-leaved plants in various agricultural crops. Its primary mechanism targets specific biochemical pathways, effectively minimizing competition for nutrients and sunlight. Defenuron is utilized in research to study herbicidal activity and crop management strategies, contributing to the development of sustainable agricultural practices. -
Herbicide
Monisouron (SSH-41) is a selective herbicide targeting post-emergence control of a range of broad-leaved and grass weeds while preserving the integrity of crops such as barley, pea, and maize. This compound demonstrates significant herbicidal activity, making it a valuable tool for research focused on weed management strategies and agricultural applications. Its selectivity profile contributes to effective weed control in diverse crop systems. -
HMG-CoA reductase Inhibitor
Atorvastatin (lysine) is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This compound is primarily utilized in research focused on hypercholesterolemia and mixed hyperlipidemia, enabling studies on lipid regulation and cardiovascular health. Its ability to modulate cholesterol levels makes it valuable for investigating therapeutic approaches for dyslipidemia-related conditions. -
HMG-CoA Reductase Inhibitor
BMS-180431 is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound effectively reduces cholesterol biosynthesis, making it relevant for research in lipid metabolism and cardiovascular disease. It is applicable in studies exploring hyperlipidemia, atherosclerosis, and related metabolic disorders. -
HMG-CoA Reductase (HMGCR) Inhibitor
Lovastatin hydroxy acid sodium is a potent inhibitor of HMG-CoA reductase (HMGCR), exhibiting a Ki of 0.6 nM. By effectively blocking the enzymatic action of HMGCR, this compound plays a critical role in cholesterol biosynthesis regulation. It is widely utilized in research to explore lipid metabolism, cardiovascular diseases, and therapeutic interventions for dyslipidemia. -
HMG-CoA Inhibitor
Pravastatin lactone is a potent HMG-CoA reductase inhibitor that functions as a metabolite of pravastatin. It effectively decreases blood cholesterol levels by inhibiting the synthesis of cholesterol in the liver. This compound is widely used in research related to lipid metabolism, cardiovascular diseases, and the development of cholesterol-lowering therapies. -
HMG-CoA Reductase (HMGCR) Inhibitor
β-Amyrin palmitate is an HMG-CoA reductase (HMGCR) inhibitor that plays a crucial role in lipid metabolism. This compound exhibits biological activity that can aid in the management of diabetes mellitus, making it a valuable reagent for research in metabolic disorders. Its ability to modulate cholesterol biosynthesis may also offer insights into cardiovascular health and related conditions. -
HMG-CoA Inhibitor
Bemfivastatin hemicalcium is an orally active inhibitor of HMG-CoA reductase (HMGCR), targeting cholesterol biosynthesis. This compound effectively promotes the liver's ability to extract lipids, leading to a significant reduction in blood lipid levels. Bemfivastatin hemicalcium is applicable in research on metabolic disorders, particularly in studying hypercholesterolemia and related conditions. -
HMG-CoA Inhibitor
Lovastatin acid is a potent competitive inhibitor of HMG-CoA reductase, with an inhibition constant (Ki) of 0.6 nM. As an active metabolite of Lovastatin, it effectively interferes with cholesterol synthesis by inhibiting the conversion of HMG-CoA to mevalonate. This compound is particularly valuable for research into hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5S)-Pitavastatin calcium is a potent HMG-CoA reductase inhibitor effective in lowering cholesterol levels. It plays a significant role in the study of cardiovascular diseases by inhibiting lipid biosynthesis and improving lipid profiles. This compound is primarily utilized in research applications focused on atherogenesis and the investigation of statin therapy mechanisms. -
HMG-CoA Reductase Inhibitor
Rosuvastatin zinc salt is a zinc-complexed form of Rosuvastatin, an HMG-CoA reductase inhibitor. This compound effectively reduces cholesterol synthesis, making it valuable in atherosclerosis research. Its mechanism of action supports studies focusing on lipid regulation and cardiovascular disease prevention. -
HMG-CoA Reductase (HMGCR)
(3S,5R)-Fluvastatin potassium is an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This compound exhibits antioxidative properties, influencing the oxidation of LDL in the presence of copper ions, akin to its 3R,5S enantiomer. Investigations have indicated that (3S,5R)-Fluvastatin potassium and its metabolites may possess anti-atherosclerotic effects through their antioxidative activities. It is commonly employed in research focused on cholesterol regulation and cardiovascular disease mitigation. -
HMG-CoA Reductase (HMGCR)
Ganoderic acid SZ is a potent inhibitor of HMG-CoA reductase (HMGCR), demonstrating superior activity compared to atorvastatin. This natural compound also significantly inhibits α-glucosidase derived from yeast, with low nanomolar IC50 values. Additionally, Ganoderic acid SZ exhibits cytotoxic effects against K562 leukemia cells, with IC50 values ranging from 10 to 20 μM. These properties make Ganoderic acid SZ a valuable tool for research in cholesterol metabolism and cancer studies. -
HMG-CoA Reductase Inhibitor
BMS-180431 sodium is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound plays a pivotal role in cholesterol biosynthesis, making it valuable for research focused on lipid metabolism and related cardiovascular diseases. Its inhibitory effects on HMG-CoA reductase provide a useful tool for studying cholesterol-lowering interventions and the underlying mechanisms of dyslipidemia. -
HMG-CoA Reductase Inhibitor
L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. This compound significantly reduces circulating serum cholesterol levels, demonstrating its efficacy in cholesterol management. Additionally, L-645164 shows potential for use in research related to central nervous system disorders, providing new avenues for investigation into therapeutic strategies. -
HMG-CoA Reductase Inhibitor
PF-3052334 is a potent, orally available inhibitor of HMG-CoA reductase, exhibiting an IC50 of 1.9 nM. This compound selectively inhibits cholesterol synthesis in hepatocytes with an IC50 of 0.9 nM, while displaying a significantly higher IC50 of 730 nM in muscle cells. PF-3052334 serves as a valuable tool for investigating hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
SQ-33600 is an HMG-CoA reductase inhibitor that exhibits cholesterol-lowering activity. It demonstrates significant selectivity, showing a much stronger inhibitory effect on rat hepatocytes (IC50: 93 nM) compared to human skin fibroblasts (IC50: 14200 nM). This compound is valuable for research on hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
Crilvastatin is a potent HMG-CoA reductase inhibitor that plays a critical role in cholesterol biosynthesis regulation. By inhibiting this key enzyme, Crilvastatin effectively lowers cholesterol levels, making it valuable for research in dyslipidemia and cardiovascular disease. This compound serves as a useful tool in studies aimed at understanding lipid metabolism and the therapeutic potential of statins in managing hyperlipidemic conditions. -
11βHSD Isozymes Inhibitor
11-Beta-hydroxyandrostenedione is an inhibitor of the 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes. This steroid is primarily produced in the adrenal glands and serves as a critical biomarker in differentiating the adrenal from the ovarian sources of hyperandrogenism by measuring plasma levels. Its specificity in inhibiting 11βHSD makes it valuable in endocrine research and the study of steroid biosynthesis pathways. -
11β-HSD1 Inhibitor
11β-HSD1-IN-24 is a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with an IC50 of 0.5 nM. This compound effectively inhibits the conversion of inactive cortisone to active cortisol, making it a valuable tool for research in metabolic diseases, particularly type 2 diabetes. Its high selectivity and potency position it as an important reagent for studying the physiological roles of glucocorticoids in metabolic pathways. -
11βHSD1 Inhibitor
UE2316 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). It has been shown to significantly enhance glucose tolerance and insulin sensitivity in uremic rat models. Additionally, UE2316 has been associated with the exacerbation of hepatic fibrosis in mice. This compound is utilized in research pertaining to metabolic disorders, including hepatic fibrosis, uremia, and diabetes mellitus. -
17β-HSD2 Inhibitor
11β-HSD2-IN-2 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), demonstrating an IC50 of 300 nM. This compound plays a crucial role in modulating steroid metabolism and is valuable for research applications investigating hormonal regulation and related disorders. Its specificity makes it a useful tool for exploring the biological effects of 17β-HSD2 inhibition in various physiological contexts. -
11β-HSD1 Inhibitor
SKI2852 is a selective, orally active inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), exhibiting IC50 values of 1.6 nM for mouse HSD1 and 2.9 nM for human HSD1. This compound plays a critical role in the modulation of local glucocorticoid metabolism, making it valuable for research focused on metabolic diseases, obesity, and related disorders. Its potent inhibitory activity positions SKI2852 as a significant tool for investigating the physiological and therapeutic implications of 11β-HSD1 modulation. -
11β-HSD Inhibitor
Tetrahydro-11-dehydrocorticosterone is an inhibitor of the 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme, which plays a critical role in the metabolism of corticosteroids. This compound is utilized in research to study the regulation of glucocorticoid action and its implications in metabolic disorders, stress response, and inflammation. By modulating 11β-HSD activity, it serves as a valuable tool for investigating the therapeutic potential of targeted interventions in hormone-related diseases. -
11β-HSD1 Inhibitor
BMS-770767 is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), which is implicated in the pathophysiology of type 2 diabetes. By selectively targeting 11β-HSD1, this compound modulates cortisol availability, influencing metabolic processes in liver and adipose tissue. BMS-770767 is utilized in research focused on obesity, metabolic syndrome, and diabetes-related conditions. -
11β-HSD1 Inhibitor
ABT-384 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with exceptional potency, exhibiting high affinity with Ki values ranging from 0.1 to 2.7 nM across rodent, monkey, and human enzyme targets. By preventing the regeneration of active cortisol, ABT-384 serves as a valuable tool in research investigating the pathophysiology of Alzheimer's disease (AD) and related conditions. Its specific action on cortisol metabolism makes it suitable for studies aimed at understanding the role of glucocorticoids in neurodegenerative disorders. -
11β-HSD1 Inhibitor
(Rac)-BMS-816336 is a potent inhibitor of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, exhibiting IC50 values of 10 nM in human cells and 68 nM in murine cells. Its mechanism of action involves the selective inhibition of 11β-HSD1, leading to modulation of glucocorticoid metabolism. This compound is useful in research applications focused on metabolic disorders, obesity, and conditions associated with dysregulated glucocorticoid action, due to its favorable metabolic stability. -
11β-HSD1 Inhibitor
HSD-016 is a selective and orally bioavailable inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with IC50 values of 11 nM, 1 nM, and 8 nM against human, mouse, and rat enzymes, respectively. This reagent plays a significant role in studies related to type 2 diabetes by modulating the conversion of inactive cortisone to active cortisol, thereby influencing glucose metabolism and insulin sensitivity. HSD-016 is valuable for investigating the therapeutic potential of 11β-HSD1 inhibition in metabolic disorders. -
11β HSD1 Inhibitor
11β-HSD1-IN-8 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) with an IC50 value of 2.3 μM against human 11β HSD1. This compound is of significant interest for research into metabolic disorders, particularly diabetes, and its potential impact on cognitive decline. By modulating the enzymatic activity of 11β HSD1, this reagent can facilitate studies aimed at understanding its role in glucocorticoid metabolism and related pathophysiological conditions. -
11β HSD1 Inhibitor
11β-HSD1-IN-7 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), demonstrating an IC50 value of 1.9 μM in human enzymatic assays. This compound is valuable for investigating the role of 11β-HSD1 in metabolic disorders such as diabetes and age-related cognitive decline. Its selective inhibition of 11β-HSD1 makes it a useful tool for research into therapeutic strategies targeting these conditions. -
11β-HSD Inhibitor
11β-HSD1-IN-1 is a selective inhibitor of 11β-hydroxydehydrogenase 1 (11β-HSD1) with an IC50 value of 52 nM. It has demonstrated biological activity relevant to modulating corticosteroid metabolism, making it a valuable tool in studies related to various metabolic and inflammatory disorders. This compound is primarily utilized in research applications focused on pain management and related therapeutic areas. -
11β-HSD Inhibitor
BVT-116429 is a selective inhibitor of 11β-HSD1, a key enzyme involved in cortisol metabolism. This compound has been shown to enhance adiponectin levels and improve glucose homeostasis in diabetic mouse models. In studies involving diabetic KKAy mice, BVT-116429 effectively reduced basal insulin levels and fasting blood glucose levels after 10 days of treatment, demonstrating a potential therapeutic role in the management of metabolic disorders. -
11β-HSD1 Inhibitor
AMG-221 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a Ki value of 12.8 nM as determined by biochemical scintillation proximity assays and an IC50 of 10.1 nM in cell-based assays. This compound demonstrates potential for modulating cortisol metabolism, making it a valuable tool for research into type 2 diabetes and related metabolic disorders. -
11β-HSD1 Inhibitor
11β-HSD1-IN-9 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with IC50 values of 0.48 µM for human and 1.3 µM for murine isoforms. This compound competes with rat 11β-HSD1, making it a valuable tool for investigating the enzyme's role in metabolic disorders. Applications include studies focused on obesity, hyperglycemia, and cognitive impairments, offering insights into the therapeutic potential of targeting 11β-HSD1 in related diseases. -
11β-HSD1 Inhibitor
11β-HSD1-IN-12 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a crucial enzyme that converts inactive glucocorticoids to their active forms, thereby influencing intracellular glucocorticoid levels. This compound is significant in research related to obesity and metabolic syndrome, providing a valuable tool for studying the therapeutic potential of modulating glucocorticoid metabolism. -
11β-HSD1 Inhibitor
11β-HSD1-IN-11 is a competitive inhibitor of 11β-HSD1, exhibiting IC50 values of 0.34 μM for rat and 0.13 μM for human enzymes. This compound effectively modulates cortisol metabolism, thereby influencing glucocorticoid signaling pathways. It is useful for studying the role of 11β-HSD1 in metabolic disorders and other physiological processes. -
11β-HSD1 Inhibitor
11β-HSD1-IN-10 is a potent inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), with an IC50 of 1.8 µM in human models. This compound is valuable for research on obesity, hyperglycemia, and cognitive impairment, providing insights into metabolic regulation and endocrine function. Its effectiveness makes it a useful tool for studying the role of glucocorticoid metabolism in various physiological and pathological conditions. -
11β-HSD Inhibitor
BMS-823778 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1, which plays a crucial role in the regulation of cortisol metabolism. This compound has demonstrated potential in modulating glucose homeostasis and is primarily investigated for its applications in type 2 diabetes research. The inhibition of 11β-HSD1 by BMS-823778 may aid in exploring therapeutic strategies for metabolic disorders and related conditions. -
CYP17A1 Substrate
11-Ketoprogesterone (11KP4) serves as a substrate for the enzymes CYP17A1 and 11β-HSD2, facilitating the conversion to 21-deoxycortisone (21dE) and 21-deoxycortisol (21dF), both of which exhibit glucocorticoid activity. This compound is pivotal for studies examining steroidogenesis and adrenal hormone metabolism. It is utilized in research applications focusing on hormonal regulation and related disorders, providing insights into steroid hormone biosynthesis pathways. -
11β-HSD1 Inhibitor
MK-0736 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a critical role in cortisol metabolism. This compound has been shown to lower blood pressure and is instrumental in research on type 2 diabetes and metabolic syndrome. Its application may support investigations into the therapeutic potential for managing metabolic disorders and related cardiovascular conditions. -
11β-HSD-1 Inhibitor
11β-HSD1-IN-6 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1), which catalyzes the conversion of active glucocorticoids such as cortisol to their inactive forms, 11-dehydrocorticosterone or cortisone. By inhibiting this enzyme, 11β-HSD1-IN-6 can modulate glucocorticoid availability and has potential applications in studies related to metabolic disorders, stress response, and associated therapeutic strategies. This compound serves as a valuable tool for investigating the biological roles of glucocorticoids and their implications in various diseases. -
11β-HSD1 Inhibitor
BMS-823778 hydrochloride is a selective and potent 11β-HSD1 inhibitor, exhibiting an IC50 of 2.3 nM against human 11β-HSD1. This compound plays a crucial role in regulating cortisol metabolism and glucose homeostasis, making it valuable in research related to metabolic disorders, obesity, and diabetes. It is particularly useful for studies investigating the effects of 11β-HSD1 inhibition on insulin sensitivity and related pathways. -
HSD1 Inhibitor
MK-0916 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD1). This compound induces mechanism-based activation of the hypothalamic-pituitary-adrenal axis, contributing to altered cortisol metabolism. MK-0916 is primarily utilized in research focused on type 2 diabetes and metabolic syndromes, providing insights into glucocorticoid regulation and potential therapeutic interventions. -
11β-HSD1 Inhibitor
UE2343 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a critical role in glucocorticoid metabolism. This compound is designed for oral administration and exhibits the ability to penetrate the blood-brain barrier. UE2343 is being researched for its potential therapeutic effects in the treatment of Alzheimer's disease, targeting neuroinflammation and cognitive decline associated with the condition.
